Abstract
ABSTRACTMycobacterium tuberculosis(Mtb), the pathogen responsible for tuberculosis (TB), is the leading cause of bacterial disease-related death worldwide. Current antibiotic regimens for the treatment of TB remain dated and suffer from long treatment times as well as the development of drug-resistance. As such, the search for novel chemical modalities that have selective or potent anti-Mtb properties remains an urgent priority, particularly against multidrug resistant (MDR) Mtb strains. Herein, we design and synthesize 35 novelbenzo[c]phenanthridinederivatives (BPD). The two most potent compounds, BPD-6 and BPD-9, accumulated within the bacterial cell and exhibited strong inhibitory activity (MIC90∼ 2-10 μM) against multipleMycobacteriumstrains, while remaining inactive against a range of other Gram-negative and Gram-positive bacteria. BPD-6 and BPD-9 were also effective in reducing Mtb viability within infected macrophages. The two BPD compounds displayed comparable efficacy to rifampicin, a critical frontline antibiotic used for the prevention and treatment of TB. Importantly, BPD-6 and BPD-9 inhibited the growth of multiple MDR Mtb clinical isolates, suggesting a completely novel mechanism of action compared to existing frontline TB dugs. The discovery of BPDs provides novel chemical scaffolds for anti-TB drug discovery.TOC/GRAPHICAL ABSTRACT
Publisher
Cold Spring Harbor Laboratory
Reference44 articles.
1. Chakaya, J. ; Khan, M. ; Ntoumi, F. ; Aklillu, E. ; Fatima, R. ; Mwaba, P. ; Kapata, N. ; Mfinanga, S. ; Hasnain, S. E. ; Katoto, P. D. M. C. ; Bulabula, A. N. H. ; Sam-Agudu, N. A. ; Nachega, J. B. ; Tiberi, S. ; McHugh, T. D. ; Abubakar, I. ; Zumla, A. Global Tuberculosis Report 2020 - Reflections on the Global TB Burden, Treatment and Prevention Efforts. Int. J. Infect. Dis. 2021, S1201-9712(21)00193-4.
2. The future for early-stage tuberculosis drug discovery
3. Current Challenges in Drug Discovery for Tuberculosis;Expert Opin. Drug Discov,2017
4. Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis
5. Modeling of Mycobacterium Tuberculosis Dormancy in Bacterial Cultures;Tuberc. Edinb. Scotl,2019